Latest News for: mab

Edit

Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention

Pharmiweb 12 Feb 2026
The results demonstrate the potential of bocunebart in severe migraine ... Valby, Denmark, February 12, 2026 - H ... Dr ... About the PROCEED migraine trial ... Bocunebart is an investigational monoclonal antibody (mAb) with a novel mechanism of action ... 38(1). p ... p ... p ... .
Edit

SK bioscience In-Licenses RSV Preventive mAb Candidate from Gates Medical Research Institute

PR Newswire 03 Feb 2026
The RSV preventive mAb candidate, engineered by Adimab in ... Based on these findings, SK bioscience plans to move swiftly into a Phase 1b clinical trial in infants to accelerate this mAb's development.
Edit

MAB Submits 34-point Memorandum To Empower Visually Impaired Community

Malaysian National News Agency 29 Jan 2026
MAB Submits 34-point Memorandum To Empower Visually Impaired Community.
Edit

CCS Consults on the Proposed Air Cargo Agreement between Qatar Airways, IAG Cargo and MAB Kargo (CCCS - Competition and Consumer Commission)

Public Technologies 23 Jan 2026
The Competition and Consumer Commission of Singapore ("CCS") is inviting public feedback on the proposed joint business agreement between Qatar Airways Group Q.C.S.C ("QR"), IAG Cargo Limited ("IAGC") and MAB Kargo Sdn.
Edit

Over 1,700 people in Cork seeking the help of money advice agency MABS amid spiralling finance woes

Irish Independent 13 Jan 2026
MABS, the national money advice and ...
Edit

Annual Report 2025(16.89 MB) (MAB Annual Report 2025 Accessible) (Mitchells & Butlers plc)

Public Technologies 05 Jan 2026
). Annual Report and Accounts 2025. Annual Report and Accounts 2025 Contents. Introduction. About us/Financial highlights/Environmental targets. At a glance 06 Welcome to. Mitchells & Butlers 08 Strategy in action. Strategic Report. 24 Chair's statement.
Edit

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal ...

Nasdaq Globe Newswire 29 Dec 2025
Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study ... .
Edit

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) (Form 8-K) (Tonix Pharmaceuticals Holding Corp)

Public Technologies 29 Dec 2025
Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) ... TNX-4800 (formerly known as mAb ...
Edit

Lockheed Martin-MAB-5-Render

Image Decatur Daily 19 Dec 2025
The 88,000-square-foot New Missile Assembly Building-5 is on track for completion by early 2026, with a formal grand opening to follow. [COURTESY RENDERING/LOCKHEED MARTIN] ... .
Edit

Team Decklid donates €2,030 to MABS Mazarrón

Spanish News Today 15 Dec 2025
 . Decklid Auto Services has made another generous contribution to the local community, delivering €2,030 in sponsorship funds raised for Race for Life 2025 to MABS Mazarrón.   ...   ...   ...   ... Image. MABS Mazarrón.
Edit

Enquyst Technologies Demonstrates First-in-Class, Chromatography-free Downstream Processing of a Monoclonal Antibody (mAb) with its Patented ...

Image The St Marys Daily Press 25 Nov 2025
A traditional mAb downstream process (DSP) requires three ...
Edit

Enquyst Technologies Demonstrates First-in-Class, Chromatography-free Downstream Processing of a Monoclonal Antibody (mAb) with its Patented Isoelectric Point Purification (IPP) Technology Platform and Announces Receipt of a National Institute for Innovation in Manufacturing Biopharmaceutical (NIIMBL) Led Gates Grand Challenge Program Award

PR Newswire 24 Nov 2025
"We are excited to continue to push the limits of the technology to solve challenges and address unmet needs in the downstream processing of mAb and advanced therapy medicinal products.".
Edit

Inflammatory Bowel Disease Treatment Market Analysis Report 2025-2033: Adoption of MAb, Biosimilars, Targeted Therapies is ...

Nasdaq Globe Newswire 20 Nov 2025
Growth is fueled by increasing diagnosis rates and advanced therapies. Asia-Pacific offers rapid growth potential amid rising healthcare investments ... .
Edit

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with ...

Nasdaq Globe Newswire 18 Nov 2025
RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity ... .
Edit

Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer (Form 6-K) (Radiopharm Theranostics Ltd)

Public Technologies 18 Nov 2025
). Radiopharm Theranostics Receives Approval to Initiate Phase 1 Therapeutic Trial of RAD 402 (KLK3-mAb with Tb161) in Advanced Prostate Cancer. RAD 402 is a humanized IgG1 internalized by prostate cells, binding KLK3 with high affinity ... ABN ... P ... E ... E ... P ... E.

Article Search

tools
×
×
×
×